Vincent Pieribone, Ph.D.
, associate professor of neurobiology, and cellular & molecular physiology at Yale and associate fellow of the John B. Pierce Laboratory, cofounded the New Haven-based pharmaceutical company Marinus in 2005, raising $29.4 million in Series-A financing in addition to receiving an SBIR grant. The company is dedicated to the development and commercialization of novel drugs to treat serious neurological, psychiatric and pain disorders.
Adam Wisnewski, Ph.D.
, senior research scientist in medicine at Yale, has received multiple Phase I and Phase II STTR grants, including $737,000 in 2011 and $607,000 in 2012 for his work with the New Haven-based startup L2 Diagnostics to develop innovative biomonitoring approaches to exposure surveillance for methylene-dipheneyl diisocyanate (MDI), which is used to make foams, coatings and other products and leads to MDI asthma in exposed workers.
Michael Hodsdon, M.D., Ph.D.
, associate professor of laboratory medicine and of pharmacology and associate director of the Yale Clinical Chemistry Laboratory, was awarded $225,000 in a Phase I SBIR grant in January 2013 for his work developing a rapid, phenotypic method relying on mass spectrometry to detect carbapenemase activity, which would help prevent drug-resistant bacterial outbreaks, a major threat to global health. His New Haven-based startup, M/Z Diagnostics, includes Thomas Murray, an assistant professor at Yale School of Medicine and assistant director of the Clinical Microbiology Laboratory at Yale New Haven Hospital; David Peaper, the assistant professor of laboratory medicine and director of the Clinical Microbiology Laboratory , and Mandar Kulkarni, who did his postdoctoral fellowship at Yale.